New study peers inside lungs to see if inhaled drug hits the mark
NCT ID NCT07530263
First seen May 13, 2026 · Last updated May 15, 2026 · Updated 2 times
Summary
This early-phase study looks at how well an inhaled antifungal drug (liposomal amphotericin B) reaches the lungs in 18 adults with chronic pulmonary aspergillosis. Participants receive two different doses on separate days, then undergo special scans and blood tests to measure drug distribution and safety. The goal is to gather information to improve future inhalation treatments, not to directly treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PULMONARY ASPERGILLOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Radboudumc
Nijmegen, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.